DK1951724T3 - Sammensmeltede bicykliske mTOR-inhibitorer - Google Patents

Sammensmeltede bicykliske mTOR-inhibitorer

Info

Publication number: DK1951724T3
Authority: DK; Denmark
Prior art keywords: merged; mtor inhibitors; bicyclic; bicyclic mtor; inhibitors
Prior art date: 2005-11-17

Application number

DK06837752.2T

Other languages

English (en)

Inventor

Xin Chen

Heather Coate

Andrew-Philip Crew

Han-Qing Dong

Ayako Honda

Mark Joseph Mulvihill

Paula A R Tavares

Jing Wang

Douglas S Werner

Kristen Michelle Mulvihill

Kam W Siu

Bijoy Panicker

Apoorba Bharadwaj

Lee D Arnold

Meizhong Jin

Brian Volk

Qinghua Weng

James David Beard

Original Assignee

Osi Pharmaceuticals Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-11-17

Filing date

2006-11-15

Publication date

2011-08-15

2006-11-15 Application filed by Osi Pharmaceuticals Llc filed Critical Osi Pharmaceuticals Llc

2011-08-15 Application granted granted Critical

2011-08-15 Publication of DK1951724T3 publication Critical patent/DK1951724T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
- C07D253/06—1,2,4-Triazines
- C07D253/065—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members
- C07D253/07—1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Transplantation (AREA)
Cardiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK06837752.2T 2005-11-17 2006-11-15 Sammensmeltede bicykliske mTOR-inhibitorer DK1951724T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US73758105P	2005-11-17	2005-11-17
US85424706P	2006-10-25	2006-10-25
PCT/US2006/044461 WO2007061737A2 (en)	2005-11-17	2006-11-15	FUSED BICYCLIC mTOR INHIBITORS

Publications (1)

Publication Number	Publication Date
DK1951724T3 true DK1951724T3 (da)	2011-08-15

Family

ID=38066461

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK06837752.2T DK1951724T3 (da)	2005-11-17	2006-11-15	Sammensmeltede bicykliske mTOR-inhibitorer

Country Status (25)

Country	Link
US (6)	US7700594B2 (da)
EP (3)	EP2325186B1 (da)
JP (2)	JP5335432B2 (da)
KR (1)	KR20080078668A (da)
CN (2)	CN102936250B (da)
AR (1)	AR056884A1 (da)
AT (1)	ATE507227T1 (da)
AU (1)	AU2006316605B2 (da)
BR (1)	BRPI0618622A2 (da)
CA (1)	CA2630271C (da)
DE (1)	DE602006021608D1 (da)
DK (1)	DK1951724T3 (da)
EA (1)	EA015463B1 (da)
ES (2)	ES2436877T3 (da)
HR (1)	HRP20110553T1 (da)
IL (1)	IL191532A0 (da)
MY (1)	MY148491A (da)
NZ (1)	NZ569050A (da)
PL (2)	PL1951724T3 (da)
PT (2)	PT1951724E (da)
RS (1)	RS51843B (da)
SI (1)	SI1951724T1 (da)
TW (1)	TWI382028B (da)
WO (1)	WO2007061737A2 (da)
ZA (1)	ZA200804237B (da)

Families Citing this family (161)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2652440T3 (es) *	2004-04-02	2018-02-02	OSI Pharmaceuticals, LLC	Inhibidores de proteína cinasa heterobicíclicos sustituidos con anillo 6,6-bicíclico
WO2006068760A2 (en)	2004-11-19	2006-06-29	The Regents Of The University Of California	Anti-inflammatory pyrazolopyrimidines
EP2308839B1 (en) *	2005-04-20	2017-03-01	Takeda Pharmaceutical Company Limited	Fused heterocyclic compounds
KR20080078668A (ko) *	2005-11-17	2008-08-27	오에스아이 파마슈티컬스, 인코포레이티드	융합된 바이사이클릭 ｍＴＯＲ 억제자
AR057960A1 (es) *	2005-12-02	2007-12-26	Osi Pharm Inc	Inhibidores de proteina quinasa biciclicos
US8575164B2 (en) *	2005-12-19	2013-11-05	OSI Pharmaceuticals, LLC	Combination cancer therapy
CA2635231C (en) *	2005-12-29	2014-07-15	Abbott Laboratories	Protein kinase inhibitors
JP5156644B2 (ja) *	2006-01-25	2013-03-06	オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー	不飽和ｍＴＯＲ阻害剤
EP1996193A2 (en) *	2006-03-13	2008-12-03	OSI Pharmaceuticals, Inc.	Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
CA2909277A1 (en)	2006-04-04	2007-10-11	Kevan M. Shokat	Kinase antagonists
WO2008141145A1 (en) *	2007-05-09	2008-11-20	Abbott Laboratories	Condensed heterocyclic compounds as inhibitors of protein kinases
US8124759B2 (en)	2007-05-09	2012-02-28	Abbott Laboratories	Inhibitors of protein kinases
WO2008141140A1 (en) *	2007-05-09	2008-11-20	Abbott Laboratories	Condensed heterocyclic compounds as inhibitors of protein kinases
WO2008148074A2 (en) *	2007-05-24	2008-12-04	Research Foundation Of State University Of New York	Inhibitors of mtor and methods of treatment using same
JP2010532756A (ja) *	2007-07-06	2010-10-14	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
WO2009046448A1 (en)	2007-10-04	2009-04-09	Intellikine, Inc.	Chemical entities and therapeutic uses thereof
US8193182B2 (en)	2008-01-04	2012-06-05	Intellikine, Inc.	Substituted isoquinolin-1(2H)-ones, and methods of use thereof
DK2240451T3 (da)	2008-01-04	2017-11-20	Intellikine Llc	Isoquinolinonderivater substitueret med en purin, der er anvendelig som pi3k-inhibitorer
US20110046144A1 (en) *	2008-01-18	2011-02-24	Mulvihill Mark J	Imidazopyrazinol derivatives for the treatment of cancers
AU2009211338B2 (en) *	2008-02-06	2011-12-15	Novartis Ag	Pyrrolo[2, 3-D] pyrimidines and use thereof as tyrosine kinase inhibitors
US20090227575A1 (en) *	2008-03-04	2009-09-10	Wyeth	7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
WO2009114874A2 (en)	2008-03-14	2009-09-17	Intellikine, Inc.	Benzothiazole kinase inhibitors and methods of use
US20100048912A1 (en)	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP2252293B1 (en) *	2008-03-14	2018-06-27	Intellikine, LLC	Kinase inhibitors and methods of use
CN101977912A (zh) *	2008-03-19	2011-02-16	Osi医药有限公司	mTOR抑制剂的盐形式
US8685995B2 (en)	2008-03-21	2014-04-01	The University Of Chicago	Treatment with opioid antagonists and mTOR inhibitors
EP2283020B8 (en) *	2008-05-19	2012-12-12	OSI Pharmaceuticals, LLC	Substituted imidazopyr-and imidazotri-azines
US20110224223A1 (en)	2008-07-08	2011-09-15	The Regents Of The University Of California, A California Corporation	MTOR Modulators and Uses Thereof
US9096611B2 (en) *	2008-07-08	2015-08-04	Intellikine Llc	Kinase inhibitors and methods of use
WO2010036380A1 (en)	2008-09-26	2010-04-01	Intellikine, Inc.	Heterocyclic kinase inhibitors
US8697709B2 (en)	2008-10-16	2014-04-15	The Regents Of The University Of California	Fused ring heteroaryl kinase inhibitors
US8110578B2 (en) *	2008-10-27	2012-02-07	Signal Pharmaceuticals, Llc	Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
US8476431B2 (en) *	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
CN102325753B (zh)	2008-12-19	2014-09-10	百时美施贵宝公司	用作激酶抑制剂的咔唑甲酰胺化合物
EP2393827B1 (en)	2009-02-05	2015-10-07	Tokai Pharmaceuticals, Inc.	Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
EP2417138B1 (en) *	2009-04-09	2019-11-27	Merck Sharp & Dohme Corp.	Pyrazolo[1, 5-a]pyrimidine derivatives as mtor inhibitors
WO2010123792A1 (en)	2009-04-20	2010-10-28	Osi Pharmaceuticals, Inc.	Preparation of c-pyrazine-methylamines
EP2427192A1 (en) *	2009-05-07	2012-03-14	OSI Pharmaceuticals, LLC	Use of osi-906 for treating adrenocortical carcinoma
EP2427195B1 (en)	2009-05-07	2019-05-01	Intellikine, LLC	Heterocyclic compounds and uses thereof
CN102471292A (zh) *	2009-07-09	2012-05-23	Osi药物有限责任公司	取代的3-氨基-5-氧代-4,5-二氢-[1,2,4]三氮烯的方法
KR101721280B1 (ko)	2009-08-17	2017-03-29	인텔리카인, 엘엘씨	헤테로사이클릭 화합물 및 이의 용도
US8658651B2 (en)	2009-09-30	2014-02-25	Merck Sharp & Dohme Corp.	Compounds that are ERK inhibitors
WO2011047384A2 (en)	2009-10-16	2011-04-21	The Regents Of The University Of California	Methods of inhibiting ire1
US9073927B2 (en)	2010-01-22	2015-07-07	Fundacion Centro Nacional De Investigaciones Oncologicas Carlos Iii	Inhibitors of PI3 kinase
EP2528919B1 (en) *	2010-01-28	2016-11-02	University of Washington	Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases
US9765037B2 (en)	2010-01-28	2017-09-19	University Of Washington Through Its Center For Commercialization	Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases
EP2992878A1 (en)	2010-02-03	2016-03-09	Signal Pharmaceuticals, LLC	Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors
EP2544672A1 (en) *	2010-03-09	2013-01-16	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
WO2011111051A1 (en)	2010-03-11	2011-09-15	Yeda Research And Development Co. Ltd.	Death associated protein 1 variants and use thereof for modulating autophagy
MX2012011912A (es)	2010-04-13	2012-11-16	Novartis Ag	Combinacion que comprende un inhibidor de cinasa 4 dependiente de ciclina o cinasa dependiente de ciclia (cdk4/6) y un inhibidor de mtor para tratar cancer.
WO2011141713A1 (en) *	2010-05-13	2011-11-17	Centro Nacional De Investigaciones Oncologicas (Cnio)	New bicyclic compounds as pi3-k and mtor inhibitors
EP2571357B1 (en)	2010-05-21	2016-07-06	Infinity Pharmaceuticals, Inc.	Chemical compounds, compositions and methods for kinase modulation
US20120028972A1 (en) *	2010-07-30	2012-02-02	Lilly Wong	Biomarker assays for detecting or measuring inhibition of tor kinase activity
EP2615916B1 (en)	2010-09-16	2017-01-04	Merck Sharp & Dohme Corp.	Fused pyrazole derivatives as novel erk inhibitors
WO2012064973A2 (en)	2010-11-10	2012-05-18	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
DK2663309T3 (da)	2011-01-10	2017-06-19	Infinity Pharmaceuticals Inc	Fremgangsmåder til fremstilling af isoquinolinoner og faste former af isoquinolinoner
JP5543039B2 (ja)	2011-02-23	2014-07-09	ファイザー・インク	神経障害治療のためのイミダゾ［５，１−ｆ］［１，２，４］トリアジン
EP2678018A4 (en)	2011-02-23	2015-09-30	Intellikine Llc	COMBINATION OF CHINESE HEMMER AND USES THEREOF
SG10201605913VA (en)	2011-07-19	2016-09-29	Merck Sharp & Dohme	4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
EP2548877A1 (en)	2011-07-19	2013-01-23	MSD Oss B.V.	4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
AU2012285988B2 (en) *	2011-07-19	2017-05-25	Merck Sharp & Dohme B.V.	4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides Btk-inhibitors
US8969363B2 (en)	2011-07-19	2015-03-03	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
KR20140063605A (ko)	2011-07-19	2014-05-27	인피니티 파마슈티칼스, 인코포레이티드	헤테로사이클릭 화합물 및 그의 용도
AU2012290056B2 (en)	2011-08-03	2015-03-19	Signal Pharmaceuticals, Llc	Identification of gene expression profile as a predictive biomarker for LKB1 status
AR091790A1 (es)	2011-08-29	2015-03-04	Infinity Pharmaceuticals Inc	Derivados de isoquinolin-1-ona y sus usos
MX370814B (es)	2011-09-02	2020-01-08	Univ California	Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
EP2793893A4 (en)	2011-11-23	2015-07-08	Intellikine Llc	IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS
UY34484A (es) *	2011-12-15	2013-07-31	Bayer Ip Gmbh	Benzotienilo-pirrolotriazinas disustituidas y sus usos
EP2791143B1 (en) *	2011-12-15	2016-02-24	Bayer Intellectual Property GmbH	Substituted benzothienyl-pyrrolotriazines and uses thereof in the treatment of cancer
US9475815B2 (en)	2012-02-23	2016-10-25	Bayer Intelletual Property Gmbh	Substituted benzothienyl-pyrrolotriazines and uses thereof
WO2013152342A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Anti-cancer mtor inhibitor and anti-androgen combination
US8940742B2 (en)	2012-04-10	2015-01-27	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
CN103374001B (zh) *	2012-04-19	2015-10-28	山东轩竹医药科技有限公司	咪唑并三嗪类mTOR抑制剂
CN103374021B (zh) *	2012-04-21	2015-10-28	通化济达医药有限公司	含有锌结合基的吡啶并嘧啶类HDAC和mTOR抑制剂
US8828998B2 (en)	2012-06-25	2014-09-09	Infinity Pharmaceuticals, Inc.	Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
AU2013323426A1 (en)	2012-09-26	2015-04-23	The Regents Of The University Of California	Modulation of ire1
AU2013203714B2 (en)	2012-10-18	2015-12-03	Signal Pharmaceuticals, Llc	Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
KR102229478B1 (ko)	2012-11-01	2021-03-18	인피니티 파마슈티칼스, 인코포레이티드	Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료
RU2015137617A (ru)	2013-03-14	2017-04-18	Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер	Агенты, подавляющие андрогенные рецепторы, и их применение
US9481667B2 (en)	2013-03-15	2016-11-01	Infinity Pharmaceuticals, Inc.	Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
CA2907726A1 (en)	2013-03-22	2014-09-25	Millennium Pharmaceuticals, Inc.	Combination of catalytic mtorc1/2 inhibitors and selective inhibitors of aurora a kinase
KR102459285B1 (ko)	2013-04-17	2022-10-27	시그날 파마소티칼 엘엘씨	1-에틸-7-(2-메틸-6-(1H-1,2,4-트리아졸-3-일)피리딘-3-일)-3,4-디하이드로피라지노[2,3-b]피라진-2(1H)-온에 관한 약학 제제, 제조방법, 고체 형태 및 사용 방법
CA2909579A1 (en)	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer
JP6382945B2 (ja)	2013-04-17	2018-08-29	シグナルファーマシューティカルズ，エルエルシー	ジヒドロピラジノ−ピラジンによる癌治療
KR102221029B1 (ko)	2013-04-17	2021-02-26	시그날 파마소티칼 엘엘씨	디하이드로피라지노-피라진을 사용한 암의 치료
WO2014172432A1 (en)	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer
TWI654979B (zh)	2013-04-17	2019-04-01	美商標誌製藥公司	使用ｔｏｒ激酶抑制劑組合療法以治療癌症之方法
WO2014172431A1 (en)	2013-04-17	2014-10-23	Signal Pharmaceuticals, Llc	Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
AU2014268700B2 (en)	2013-05-20	2018-07-05	University Of Washington Through Its Center For Commercialization	5-aminopyrazole-4-carboxamide inhibitors of CDPK1 from T. gondii and C. parvum
CN113831345A (zh)	2013-05-29	2021-12-24	西格诺药品有限公司	二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途
CN105764502A (zh)	2013-07-26	2016-07-13	现代化制药公司	改善比生群及其类似物及衍生物的治疗益处的组合方法
KR20160058774A (ko)	2013-08-12	2016-05-25	토카이 파마슈티컬, 아이엔씨.	안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
US9751888B2 (en)	2013-10-04	2017-09-05	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
PL3052485T3 (pl)	2013-10-04	2022-02-28	Infinity Pharmaceuticals, Inc.	Związki heterocykliczne i ich zastosowania
CA2931431A1 (en)	2013-12-05	2015-06-11	Acerta Pharma B.V.	Therapeutic combination of a pi3k inhibitor and a btk inhibitor
EP3094314B1 (en)	2014-01-16	2021-06-23	MUSC Foundation For Research Development	Targeted nanocarriers for the administration of immunosuppressive agents
US10272083B2 (en)	2014-01-21	2019-04-30	Acerta Pharma B.V.	Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
BR112016017112A2 (pt)	2014-01-24	2017-08-08	Ai Therapeutics Inc	Composições de apilimod e métodos de uso das mesmas
CA2943075C (en)	2014-03-19	2023-02-28	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US9937171B2 (en)	2014-04-11	2018-04-10	Acerta Pharma B.V.	Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
US20150320755A1 (en)	2014-04-16	2015-11-12	Infinity Pharmaceuticals, Inc.	Combination therapies
EP3131551A4 (en)	2014-04-16	2017-09-20	Signal Pharmaceuticals, LLC	SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
NZ714742A (en)	2014-04-16	2017-04-28	Signal Pharm Llc	Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
JP2017518307A (ja)	2014-06-02	2017-07-06	チルドレンズメディカルセンターコーポレーション	免疫調節のための方法および組成物
RU2016149812A (ru)	2014-06-06	2018-07-17	Флексус Байосайенсиз, Инк.	Иммунорегулирующие средства
WO2015193740A2 (en)	2014-06-17	2015-12-23	Acerta Pharma B.V.	Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor
RS62713B1 (sr)	2014-08-11	2022-01-31	Acerta Pharma Bv	Terapeutske kombinacije btk inhibitora i bcl-2 inhibitora
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US10023576B2 (en)	2014-10-22	2018-07-17	Bristol-Myers Squibb Company	Heteroaryl substituted pyrrolotriazine amine compounds as PI3K inhibitors
US10214537B2 (en)	2014-10-22	2019-02-26	Bristol-Myers Squibb Company	Bicyclic heteroaryl amine compounds
AR102537A1 (es) *	2014-11-05	2017-03-08	Flexus Biosciences Inc	Agentes inmunomoduladores
MX2017005462A (es)	2014-11-05	2017-07-28	Flexus Biosciences Inc	Agentes inmunorreguladores.
UY36390A (es)	2014-11-05	2016-06-01	Flexus Biosciences Inc	Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
JP6705828B2 (ja)	2014-11-07	2020-06-03	エイアイ・セラピューティクス・インコーポレーテッド	腎癌の処置に使用するためのアピリモド
PT3215157T (pt)	2014-11-07	2019-07-12	Ai Therapeutics Inc	Apilimod para utilização no tratamento de melanoma
AU2015345054B2 (en)	2014-11-14	2020-03-05	Nerviano Medical Sciences S.R.L.	6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors
WO2016106623A1 (en)	2014-12-31	2016-07-07	Merck Sharp & Dohme Corp.	Benzamide imidazopyrazine btk inhibitors
JP6508324B2 (ja) *	2015-02-19	2019-05-08	Jnc株式会社	ベンゾチオフェンを有する液晶性化合物、液晶組成物および液晶表示素子
WO2016160102A1 (en)	2015-03-31	2016-10-06	Lam Therapeutics, Inc.	Active metabolites of apilimod and uses thereof
WO2016183071A1 (en)	2015-05-11	2016-11-17	Incyte Corporation	Hetero-tricyclic compounds and their use for the treatment of cancer
WO2017002095A1 (en)	2015-07-02	2017-01-05	Acerta Pharma B.V.	Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
US9708333B2 (en)	2015-08-12	2017-07-18	Incyte Corporation	Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors
US10053465B2 (en)	2015-08-26	2018-08-21	Incyte Corporation	Pyrrolopyrimidine derivatives as TAM inhibitors
NZ740616A (en)	2015-09-14	2023-05-26	Infinity Pharmaceuticals Inc	Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
CN105732460A (zh) *	2016-02-03	2016-07-06	常州工程职业技术学院	一种吲哚类化合物的合成方法
US10722484B2 (en)	2016-03-09	2020-07-28	K-Gen, Inc.	Methods of cancer treatment
WO2017161116A1 (en)	2016-03-17	2017-09-21	Infinity Pharmaceuticals, Inc.	Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
TWI753892B (zh) *	2016-03-28	2022-02-01	美商英塞特公司	作為ｔａｍ抑制劑之吡咯并三嗪化合物
CN115650985B (zh)	2016-04-15	2024-08-02	癌症研究科技有限公司	作为ret激酶抑制剂的杂环化合物
WO2017178845A1 (en)	2016-04-15	2017-10-19	Cancer Research Technology Limited	Heterocyclic compounds as ret kinase inhibitors
WO2017214269A1 (en)	2016-06-08	2017-12-14	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
IL263680B2 (en)	2016-06-24	2025-10-01	Infinity Pharmaceuticals Inc	PI3K inhibitors for use in combination with a second therapeutic agent for the treatment, management or prevention of cancer
GB201705971D0 (en)	2017-04-13	2017-05-31	Cancer Res Tech Ltd	Inhibitor compounds
AU2018263886C1 (en) *	2017-05-02	2022-12-22	Revolution Medicines, Inc.	Rapamycin analogs as mTOR inhibitors
SG11201912403SA (en)	2017-06-22	2020-01-30	Celgene Corp	Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
JP7341122B2 (ja) *	2017-08-15	2023-09-08	石薬集団中奇制薬技術（石家庄）有限公司	Ｆｇｆｒ阻害剤及びその医薬品の用途
AU2018341571A1 (en)	2017-09-27	2020-04-23	AI Therapeutics, Inc.	Therapeutic methods relating to HSP90 inhibitors
MA50655B1 (fr)	2017-09-27	2021-11-30	Incyte Corp	Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam
FR3075794A1 (fr)	2017-12-21	2019-06-28	Galderma Research & Development	Nouveaux composes inhibiteurs de mtor
FR3075795A1 (fr)	2017-12-21	2019-06-28	Galderma Research & Development	Nouveaux composes inhibiteurs de mtor
EA202091777A1 (ru) *	2018-01-26	2020-10-14	Бристол-Маерс Сквибб Компани	Аминопирролотриазины в качестве ингибиторов киназы
WO2019157516A1 (en)	2018-02-12	2019-08-15	resTORbio, Inc.	Combination therapies
CR20230030A (es)	2018-02-27	2023-03-10	Incyte Corp	Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b (divisional 2020-0441)
FI3788049T3 (fi)	2018-05-01	2023-05-30	Revolution Medicines Inc	C40-, c28- ja c-32-liittyneitä rapamysiinianalogeja mtor-estäjinä
MX2020011564A (es)	2018-05-01	2021-01-29	Revolution Medicines Inc	Analogos de rapamicina unidos a c26 como inhibidores de mtor.
MX2020012376A (es)	2018-05-18	2021-03-09	Incyte Corp	Derivados de pirimidina fusionados como inhibidores de los receptores de adenosina a2a/a2b.
WO2019232403A1 (en)	2018-06-01	2019-12-05	Cornell University	Combination therapy for pi3k-associated disease or disorder
SG11202012447YA (en)	2018-06-15	2021-01-28	Navitor Pharm Inc	Rapamycin analogs and uses thereof
MD3813800T2 (ro)	2018-06-29	2025-10-31	Incyte Corp	Formulări de inhibitor al AXL/MER
MX2021000116A (es)	2018-07-05	2021-03-29	Incyte Corp	Derivados de pirazina fusionados como inhibidores de a2a/a2b.
JP2022500384A (ja)	2018-09-10	2022-01-04	ミラティセラピューティクス，インコーポレイテッド	組み合わせ療法
TWI829857B (zh)	2019-01-29	2024-01-21	美商英塞特公司	作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
EA202192133A1 (ru) *	2019-01-31	2022-02-09	Байер Акциенгезельшафт	Моногидрат гидрохлорида рогаратиниба и его твердые состояния
US11819476B2 (en)	2019-12-05	2023-11-21	Janssen Pharmaceutica Nv	Rapamycin analogs and uses thereof
CN115697343A (zh)	2020-03-06	2023-02-03	因赛特公司	包含axl/mer和pd-1/pd-l1抑制剂的组合疗法
EP4294431A4 (en)	2021-02-16	2025-05-07	Barinthus Biotherapeutics North America, Inc.	Self-assembling nanoparticles based on amphiphilic peptides
US20240382628A1 (en)	2021-07-15	2024-11-21	President And Fellows Of Harvard College	Compositions and methods relating to cells with adhered particles
TW202402277A (zh)	2022-05-25	2024-01-16	美商銳新醫藥公司	以mtor抑制劑治療癌症之方法
WO2024092030A1 (en)	2022-10-25	2024-05-02	Vaccitech North America, Inc.	Self-assembling nanoparticles
CN118754873B (zh) *	2024-06-27	2025-03-07	广东医科大学	一种环丁烷吲哚衍生物及其制备方法和应用
CN118994167B (zh) *	2024-08-09	2025-09-12	南京健康产业研究院	一种咪唑并[1,5-a]吡嗪类抗肿瘤化合物及其制备方法和应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE791025A (fr) *	1971-11-19	1973-05-07	Allen & Hanburys Ltd	Composes heterocycliques
KR970706288A (ko) *	1994-09-29	1997-11-03	베르너 발데크, 안네테 반네르	피롤로[2, 3-d]피리미딘 및 그의 용도(Pyrrolo[2, 3-d]Pyrimidines and Their Use)
US6071891A (en) *	1996-11-22	2000-06-06	Regents Of The University Of Minnesota	Insulin-like growth factor 1 receptors (IGF-1R) antisense oligonucleotide cells composition
ES2202827T3 (es) *	1997-03-19	2004-04-01	ABBOTT GMBH & CO. KG	Pirrolo(2,3-d)pirimidinas y su uso como inhibidores de la tirosina kinasa.
US7863444B2 (en) *	1997-03-19	2011-01-04	Abbott Laboratories	4-aminopyrrolopyrimidines as kinase inhibitors
EP1140938B1 (en) *	1999-01-11	2003-08-27	Princeton University	High affinity inhibitors for target validation and uses thereof
BR0014073A (pt)	1999-09-17	2002-07-16	Abbott Gmbh & Co Kg	Pirazolopirimidinas como agentes terapêuticos
HUP0303363A2 (hu)	1999-09-17	2004-07-28	Abbott Gmbh & Co., Kg	Kináz-inhibitor hatású heterociklusos vegyületek alkalmazása gyógyszerkészítmények előállítására
US6921763B2 (en) *	1999-09-17	2005-07-26	Abbott Laboratories	Pyrazolopyrimidines as therapeutic agents
US6660731B2 (en) *	2000-09-15	2003-12-09	Vertex Pharmaceuticals Incorporated	Pyrazole compounds useful as protein kinase inhibitors
WO2003022852A2 (en) *	2001-09-11	2003-03-20	Smithkline Beecham Corporation	Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
TW200306819A (en)	2002-01-25	2003-12-01	Vertex Pharma	Indazole compounds useful as protein kinase inhibitors
US20040209930A1 (en) *	2002-10-02	2004-10-21	Carboni Joan M.	Synergistic methods and compositions for treating cancer
UA80171C2 (en) *	2002-12-19	2007-08-27	Pfizer Prod Inc	Pyrrolopyrimidine derivatives
CA2515515A1 (en)	2003-02-18	2004-09-02	Whitehead Institute For Biomedical Research	Mtor kinase-associated proteins
US7459554B2 (en) *	2003-10-15	2008-12-02	Osi Pharmaceuticals, Inc.	Imidazopyrazine tyrosine kinase inhibitors
EP1682564A1 (en)	2003-10-27	2006-07-26	Genelabs Technologies, Inc.	METHODS FOR PREPARING 7-(2 -SUBSTITUTED-s-D-RIBOFURANO SYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO 2,3-D\|PYRIMIDINE DERIVATIVES
CA2543090A1 (en) *	2003-10-27	2005-06-16	Genelabs Technologies, Inc.	Nucleoside compounds for treating viral infections
WO2005047289A1 (en) *	2003-11-17	2005-05-26	Pfizer Products Inc.	Pyrrolopyrimidine compounds useful in treatment of cancer
JP2007514759A (ja) *	2003-12-19	2007-06-07	タケダサンディエゴインコーポレイテッド	キナーゼ阻害剤
ES2652440T3 (es) *	2004-04-02	2018-02-02	OSI Pharmaceuticals, LLC	Inhibidores de proteína cinasa heterobicíclicos sustituidos con anillo 6,6-bicíclico
MX2007000610A (es) *	2004-07-16	2007-03-07	Pfizer Prod Inc	Tratamiento de combinacion para enfermedades malignas no hematologicas usando un anti-cuerpo de receptor de factor i de crecimiento de tipo anti-insulina.
TW200613306A (en) *	2004-07-20	2006-05-01	Osi Pharm Inc	Imidazotriazines as protein kinase inhibitors
WO2006068760A2 (en)	2004-11-19	2006-06-29	The Regents Of The University Of California	Anti-inflammatory pyrazolopyrimidines
WO2006081425A1 (en)	2005-01-28	2006-08-03	Whitehead Institute For Biomedical Research	Phosphorylation and regulation of akt/pkb by the rictor-mtor complex
JP2009511935A (ja)	2005-10-18	2009-03-19	ジョージメイソンインテレクチュアルプロパティーズインク．	ｍＴＯＲ経路テラノスティック
JP5116687B2 (ja) *	2005-11-02	2013-01-09	バイエル・ファルマ・アクチェンゲゼルシャフト	がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
KR20080078668A (ko)	2005-11-17	2008-08-27	오에스아이 파마슈티컬스, 인코포레이티드	융합된 바이사이클릭 ｍＴＯＲ 억제자
AR057960A1 (es)	2005-12-02	2007-12-26	Osi Pharm Inc	Inhibidores de proteina quinasa biciclicos
US20080299113A1 (en)	2005-12-19	2008-12-04	Arnold Lee D	Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents
CA2635231C (en) *	2005-12-29	2014-07-15	Abbott Laboratories	Protein kinase inhibitors
JP5156644B2 (ja) *	2006-01-25	2013-03-06	オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー	不飽和ｍＴＯＲ阻害剤
EP1996193A2 (en) *	2006-03-13	2008-12-03	OSI Pharmaceuticals, Inc.	Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
BRPI0709699A2 (pt)	2006-03-29	2011-07-26	Foldrx Pharmaceuticals Inc	inibiÇço da toxidez da alfa-sinucleina
CA2909277A1 (en)	2006-04-04	2007-10-11	Kevan M. Shokat	Kinase antagonists
DE102006016426A1 (de)	2006-04-07	2007-10-11	Merck Patent Gmbh	Neuartige Cyclobutyl-Verbindungen als Kinase-Inhibitoren
WO2008070100A1 (en)	2006-12-05	2008-06-12	University Of South Florida	Compositions including triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof
JP2010532756A (ja) *	2007-07-06	2010-10-14	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
JP2010532758A (ja) *	2007-07-06	2010-10-14	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	組み合わせ抗癌療法
JP2011500657A (ja) *	2007-10-15	2011-01-06	アストラゼネカアクチボラグ	組合せ０５９
CN101977912A (zh) *	2008-03-19	2011-02-16	Osi医药有限公司	mTOR抑制剂的盐形式
CN102471292A (zh)	2009-07-09	2012-05-23	Osi药物有限责任公司	取代的3-氨基-5-氧代-4,5-二氢-[1,2,4]三氮烯的方法
EP2459191A1 (en)	2009-07-31	2012-06-06	OSI Pharmaceuticals, LLC	Mtor inhibitor and angiogenesis inhibitor combination therapy
EP2544672A1 (en)	2010-03-09	2013-01-16	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy

2006
- 2006-11-15 KR KR1020087014589A patent/KR20080078668A/ko not_active Ceased
- 2006-11-15 US US11/599,663 patent/US7700594B2/en active Active
- 2006-11-15 ES ES11155270.9T patent/ES2436877T3/es active Active
- 2006-11-15 PL PL06837752T patent/PL1951724T3/pl unknown
- 2006-11-15 PT PT06837752T patent/PT1951724E/pt unknown
- 2006-11-15 HR HR20110553T patent/HRP20110553T1/hr unknown
- 2006-11-15 BR BRPI0618622-0A patent/BRPI0618622A2/pt not_active IP Right Cessation
- 2006-11-15 EP EP11155268.3A patent/EP2325186B1/en active Active
- 2006-11-15 EP EP06837752A patent/EP1951724B1/en active Active
- 2006-11-15 PT PT111552709T patent/PT2385053E/pt unknown
- 2006-11-15 DK DK06837752.2T patent/DK1951724T3/da active
- 2006-11-15 RS RS20110337A patent/RS51843B/sr unknown
- 2006-11-15 AU AU2006316605A patent/AU2006316605B2/en not_active Ceased
- 2006-11-15 JP JP2008541334A patent/JP5335432B2/ja not_active Expired - Fee Related
- 2006-11-15 CN CN201210369830.2A patent/CN102936250B/zh not_active Expired - Fee Related
- 2006-11-15 EA EA200801341A patent/EA015463B1/ru not_active IP Right Cessation
- 2006-11-15 CN CNA2006800430785A patent/CN101316845A/zh active Pending
- 2006-11-15 NZ NZ569050A patent/NZ569050A/en not_active IP Right Cessation
- 2006-11-15 AT AT06837752T patent/ATE507227T1/de active
- 2006-11-15 WO PCT/US2006/044461 patent/WO2007061737A2/en not_active Ceased
- 2006-11-15 CA CA2630271A patent/CA2630271C/en not_active Expired - Fee Related
- 2006-11-15 EP EP11155270.9A patent/EP2385053B1/en active Active
- 2006-11-15 SI SI200631064T patent/SI1951724T1/sl unknown
- 2006-11-15 ES ES06837752T patent/ES2365869T3/es active Active
- 2006-11-15 PL PL11155270T patent/PL2385053T3/pl unknown
- 2006-11-15 DE DE602006021608T patent/DE602006021608D1/de active Active
- 2006-11-15 MY MYPI20081660A patent/MY148491A/en unknown
- 2006-11-16 TW TW095142464A patent/TWI382028B/zh not_active IP Right Cessation
- 2006-11-17 AR ARP060105058A patent/AR056884A1/es not_active Application Discontinuation
2008
- 2008-05-16 ZA ZA200804237A patent/ZA200804237B/xx unknown
- 2008-05-18 IL IL191532A patent/IL191532A0/en unknown
- 2008-12-02 US US12/326,536 patent/US7923555B2/en active Active
2009
- 2009-11-09 JP JP2009255728A patent/JP4491510B2/ja not_active Expired - Fee Related
- 2009-11-20 US US12/622,545 patent/US7943767B2/en active Active
2011
- 2011-04-13 US US13/085,722 patent/US20110190496A1/en not_active Abandoned
- 2011-05-13 US US13/106,954 patent/US8314111B2/en active Active
2013
- 2013-02-15 US US13/767,947 patent/US8796455B2/en active Active

Also Published As

Publication number	Publication date
EP2325186A3 (en)	2011-10-26
IL191532A0 (en)	2008-12-29
PT1951724E (pt)	2011-08-02
CA2630271C (en)	2014-04-08
JP2010065049A (ja)	2010-03-25
PL2385053T3 (pl)	2014-05-30
RS51843B (sr)	2012-02-29
US7700594B2 (en)	2010-04-20
ATE507227T1 (de)	2011-05-15
CN101316845A (zh)	2008-12-03
US20130165651A1 (en)	2013-06-27
ZA200804237B (en)	2009-09-30
JP2009519222A (ja)	2009-05-14
MY148491A (en)	2013-04-30
US20070112005A1 (en)	2007-05-17
US8796455B2 (en)	2014-08-05
TWI382028B (zh)	2013-01-11
HRP20110553T1 (hr)	2011-09-30
US20090163468A1 (en)	2009-06-25
EP2325186B1 (en)	2014-10-08
JP4491510B2 (ja)	2010-06-30
ES2365869T3 (es)	2011-10-11
ES2436877T3 (es)	2014-01-07
EA015463B1 (ru)	2011-08-30
EP2385053A3 (en)	2012-02-29
PL1951724T3 (pl)	2011-09-30
CN102936250B (zh)	2014-07-09
WO2007061737A2 (en)	2007-05-31
NZ569050A (en)	2010-11-26
US20100099679A1 (en)	2010-04-22
US8314111B2 (en)	2012-11-20
HK1121158A1 (en)	2009-04-17
EP2325186A2 (en)	2011-05-25
TW200801006A (en)	2008-01-01
US7923555B2 (en)	2011-04-12
EP2385053A2 (en)	2011-11-09
CA2630271A1 (en)	2007-05-31
PT2385053E (pt)	2013-12-17
AU2006316605B2 (en)	2012-04-26
BRPI0618622A2 (pt)	2011-09-06
AU2006316605A1 (en)	2007-05-31
DE602006021608D1 (de)	2011-06-09
US7943767B2 (en)	2011-05-17
SI1951724T1 (sl)	2011-09-30
WO2007061737A3 (en)	2007-12-06
EP1951724B1 (en)	2011-04-27
KR20080078668A (ko)	2008-08-27
US20110190496A1 (en)	2011-08-04
CN102936250A (zh)	2013-02-20
EP2385053B1 (en)	2013-10-02
EP1951724A2 (en)	2008-08-06
JP5335432B2 (ja)	2013-11-06
EA200801341A1 (ru)	2008-12-30
US20110218183A1 (en)	2011-09-08
AR056884A1 (es)	2007-10-31

Publication	Publication Date	Title
DK1951724T3 (da)	2011-08-15	Sammensmeltede bicykliske mTOR-inhibitorer
FIC20230027I1 (fi)	2023-08-02	Tremelimumabi
LT2495016T (lt)	2020-02-10	Bicikliniai heteroarilų junginiai
ATE533770T1 (de)	2011-12-15	Pyrazolopyrimidine als proteinkinaseinhibitoren
DE602006016980D1 (de)	2010-10-28	Stellungsverfahren dafür
ATE501142T1 (de)	2011-03-15	Als proteinkinaseinhibitoren geeignete phenylacetamide
DE602006002951D1 (de)	2008-11-13	Verbinder
FI20055649L (fi)	2007-06-08	Paikanmääritystekniikoita
ATE530545T1 (de)	2011-11-15	Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
DE602004025215D1 (de)	2010-03-11	Tastsonde
EP1909094A4 (en)	2014-12-17	BOWL
DK1925212T3 (da)	2017-01-02	Indkapslet snack
ATE493403T1 (de)	2011-01-15	Kinaseinhibitoren
DE602006019809D1 (de)	2011-03-10	Verbinder
EP1916896A4 (en)	2010-08-11	NOT STEROID-antiandrogens
DE602006016205D1 (de)	2010-09-30	Verbinder
DE502005000300D1 (de)	2007-02-22	Tastkopf
EP1910272A4 (en)	2010-08-04	Renin Inhibitors
DE602006004811D1 (de)	2009-03-05	Prüfvorrichtung
DE602006021285D1 (de)	2011-05-26	Mikrotomklinge
DE602006018950D1 (de)	2011-01-27	N-dihydroxyalkyl-substitutierte 2-oxoimidazolderivate
FI20050681A0 (fi)	2005-06-22	Paikoitusmenetelmä
ATE454934T1 (de)	2010-01-15	Drehteller
DE602006002203D1 (de)	2008-09-25	Prüfgerät
ATE423770T1 (de)	2009-03-15	Benzoyltetrahydropyridine als glyt-1-inhibitoren